NEW YORK, Aug. 11, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or...
NEW YORK, Aug. 11, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO). Shareholders who purchased shares of NVO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment....
NEW YORK, Aug. 10, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between May 7, 2025 and July 28, 2025, both dates inclusive (the "Class...
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming September 30, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO) securities between May 7, 2025, to July 28, 2025, inclusive (the “Class Period”). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN NOVO NORDISK A/S (NVO), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONGOING
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Novo To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Novo between May 7, 2025, to July 28, 2025 and would like to discuss your...
Bagsværd, Denmark, 8 August 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk.
NEW YORK, Aug. 8, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Novo investors who were adversely affected by...
NEW YORK, Aug. 7, 2025 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo Nordisk" or "the Company") (NYSE: NVO) and certain of its...
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO) securities between May 7, 2025, to July 28, 2025, inclusive (the “Class Period”). Novo Nordisk investors have until September 30, 2025 to file a lead plaintiff motion. IF YOU SUFFERED A LOSS ON YO
Bagsværd, Denmark, 7 August 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
NEW YORK, Aug. 7, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO). Shareholders who purchased shares of NVO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment....
NEW YORK, Aug. 6, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or...
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO) securities between May 7, 2025, to July 28, 2025, inclusive (the “Class Period”). Novo Nordisk investors have until September 30, 2025 to file a lead plaintiff motion. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN NOVO NORDISK A/S (NVO), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO
LOS ANGELES--(BUSINESS WIRE)--Law Offices of Frank R. Cruz Encourages Novo Nordisk A/S (NVO) Investors To Inquire About Securities Fraud Class Action
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that an investor filed a class action lawsuit on behalf of purchasers and acquirers of Novo Nordisk A/S (NYSE: NVO) securities between May 7, 2025 and July 28, 2025, both dates inclusive (the “Class Period”). Novo Nordisk is a pharmaceutical company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegat
Novo Nordisk and Deep Apple ink a deal to develop oral therapies targeting a novel GPCR for cardiometabolic diseases, including obesity.
Semaglutide drugs now include rare vision risk warning as studies link long-term use to optic neuropathy, macular degeneration, and kidney cancer.
Shares of Novo Nordisk Inc. (NYSE: NVO) are trading lower Tuesday after a new study raised concerns about a potential link between GLP-1 weight loss drugs like Ozempic and an increased risk of kidney cancer.
Regeneron highlighted that about 35% of weight loss from semaglutide alone was due to lean mass loss, which combo therapies aim to reduce.
Novo Nordisk CEO steps down after pressure from shareholders. Former CEO to join board as observer. Company remains optimistic amid mixed signals.
Weight loss drugs like semaglutide could add £4.5 billion to the UK economy annually, boosting productivity and reducing alcohol use, though high costs may limit broad access.
Novo Nordisk and Septerna enter $2.2 billion deal to develop oral small-molecule therapies targeting obesity, diabetes, and cardiometabolic diseases.
Novo Nordisk reports phase 3 data showing weekly Sogroya matched or outperformed daily hormone therapy in multiple pediatric growth disorders.
Novo Nordisk slashed its 2025 sales forecast citing lower-than-expected penetration of its branded GLP-1 weight loss and diabetes treatments.
The court ruled in favor of Novo Nordisk and the FDA, rejecting a compounding pharmacy group's attempt to stop the FDA's decision on semaglutide shortage.
Billionaire entrepreneur Mark Cuban has expressed support for President Donald Trump's 2025 healthcare executive order, emphasizing its potential to reform the role of Pharmacy Benefit Managers (PBMs) in the U.S. healthcare system.
FDA and Novo Nordisk warn about counterfeit Ozempic in the U.S. with fake serial numbers, posing risks due to unknown contents and unverified sterility.
